Document:

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                                                   EXHIBIT 10.11

              CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY
                  WITH THE SECURITIES AND EXCHANGE COMMISSION.
                       ASTERISKS (*) DENOTE SUCH OMISSIONS

                        DEVELOPMENT AND SUPPLY AGREEMENT

                                   (ABARELIX)

      THIS DEVELOPMENT AND SUPPLY AGREEMENT (this "Agreement") effective as of
June 21, 2000 (the "Effective Date"), is by and between UCB S.A., with
registered office at Allee de la Recherche 60, B-1070 Brussels, Belgium ("UCB")
and Amgen Inc., with its principal place of business at One Amgen Center Drive,
Thousand Oaks, California 91320-1799, USA ("Amgen").

                                   WITNESSETH:

      WHEREAS, by agreement dated March 12, 1998 ("UCB-Praecis Agreement"), UCB
had entered into a contract with Praecis Pharmaceutical Incorporated ("Praecis")
for the development and supply of the active pharmaceutical ingredient for a
compound identified as PPI-149, USAN name "Abarelix", to which Praecis has the
exclusive worldwide rights as licensee. The active pharmaceutical ingredient for
Abarelix to be manufactured by UCB pursuant to this Agreement shall be referred
to as "API."

      WHEREAS, by agreement dated March 8, 1999 and subsequently amended (as
amended, the "Amended and Restated Binding Agreement in Principle," referred to
herein as the "Amgen-Praecis Agreement"), Amgen entered into a contract with
Praecis whereby Amgen would, INTER ALIA, assume responsibility for the
manufacture of Finished Product, including taking over responsibility for
dealing with subcontractors involved in the various stages of manufacture of the
Finished Product, such as UCB.

      WHEREAS, Amgen, on May 22, 2000, notified Praecis of its intent to assume
responsibility for the manufacture of Finished Product, effective June 21, 2000,
consistent with the Amgen-Praecis Agreement.

      WHEREAS, Amgen desires to contract with UCB for the supply of API
manufactured by an existing process described as "*** Synthesis," *** upon the
terms and subject to the conditions set forth in this Agreement.

      WHEREAS, UCB is willing to manufacture and supply API *** all upon the
terms and subject to the conditions set forth in this Agreement.

                                        1
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

      WHEREAS, both parties intend for this Agreement to supersede and replace
the UCB-Praecis Agreement in its entirety, and that both parties will take
whatever steps are necessary to terminate the UCB-Praecis Agreement upon
execution of this Agreement.

      NOW THEREFORE, in consideration of the foregoing premises, which are
incorporated into and made a part of this Agreement, and of the mutual covenants
which are recited herein, the parties agree as follows:

                                   ARTICLE ONE
                                   DEFINITIONS

      When used in this Agreement or any Exhibit hereto, each of the following
capitalized terms shall have the meanings set forth in this Article One. Any
terms defined elsewhere in this Agreement shall be given equal weight and
importance as though set forth in this Article.

1.1   "AFFILIATE" shall mean with respect to either party, any person,
corporation, company, partnership, joint venture or other entity controlling,
controlled by or under common control with such party. For such purpose, the
term "control" means the holding of 50% or more of the common voting stock or
ordinary shares in, or the right to appoint 50% or more of the directors of, or
the right to share in 50% or more of the profits of, said corporation, company,
partnership, joint venture, or entity. For purposes of this Agreement only,
Praecis and its Affiliates shall be considered Affiliates of Amgen, despite the
fact that Amgen does not control, is not controlled by and is not under common
control with Praecis.

1.2   "API" shall mean the bulk active pharmaceutical ingredient of Abarelix,
meeting the Specifications contained herein. The API, including its identity and
associated know-how and data related thereto, shall be deemed Confidential
Information of Amgen.

1.3   "BATCH" shall mean a single lot of API Manufactured by UCB.

1.4   "BATCH RECORD" shall mean the compilation of the information needed to
determine lot disposition including but not limited to the manufacture
procedure, raw material information, review documentation and test results, and
shall include the certificate of analysis.

1.5   "CMC" shall mean the Chemistry, Manufacture and Controls section of the
NDA or the corresponding sections of corresponding filings with other Regulatory
Agencies.

1.6   "CONFIDENTIAL INFORMATION" shall mean all confidential and proprietary
information, materials, know-how and other data, both technical and nontechnical
of a Party which is disclosed by such Party at any time prior to or during the
term of this Agreement pursuant to or in furtherance of this Agreement, except
that which the Party receiving such Confidential Information can establish by
competent evidence:

                                        2
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

      (a) is or later becomes generally available to the public by use,
      publication of the like, through no fault of the receiving Party, its
      agents or employees; or
      (b) is obtained from a third party without restriction who had legal
      right to disclose the same to the receiving Party; or
      (c) the receiving Party already possessed and obtained from a source
      other than the disclosing Party, as evidenced by its written records,
      predating receipt thereof from the disclosing Party; or
      (d) is independently developed by the receiving Party without the use of
      Confidential Information belonging to the disclosing Party as evidenced by
      the receiving Party's written records.

1.7   "DMF" shall mean a Drug Master File as defined by the FDA for filing of
approval of a contract manufacturer site, or corresponding filings with other
Regulatory Agencies.

1.8   "EMEA" shall mean the European Medicines Evaluation Agency and successor
entities.

1.9   "EP" shall mean the European Pharmacopoeia as in effect from time to time.

1.10  "FACILITY" shall mean UCB's facility located at Braine-L'Alleud, Belgium.

1.11  "FDA" shall mean the United States Food and Drug Administration and
successor entities.

1.12  "FINISHED PRODUCT" shall mean pharmaceutical compositions containing API
for treatment of disease as used by an end user or consumer.

1.13  "CGMPS" shall mean the general rules for all aspects of human
pharmaceutical manufacture, including buildings and facilities, personnel,
equipment, drug components and containers, production, packaging and labeling,
and record-keeping, and include the regulations promulgated by the FDA, see 21
C.F.R. Parts 210, 211 and 600; EU Guide to good manufacturing practice for
medicinal products; published FDA Guidance Documents; equivalent Japanese
regulations and guidelines; and accepted industry practice.

1.14  "JP" shall mean the Japanese Pharmacopoeia as in effect from time to time.

1.15  "MANUFACTURE" shall mean the manufacture of API from raw materials,
according to *** Synthesis ***, to meet the relevant Specifications. Manufacture
shall include, without limitation, assembly, synthesis and purification of the
API. "MANUFACTURING" shall have comparable meaning.

                                        3
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

1.16  "MHW" shall mean the Japanese Ministry of Health and Welfare and successor
entities.

1.17  "NDA" shall mean New Drug Application as filed by Praecis and/or Amgen
with FDA for approval of commercial sale of the Finished Product.

1.18  "PARTIES" shall mean Amgen and UCB and "PARTY" shall mean either of them.

1.19  "QUALITY EXHIBIT" shall mean the procedures, requirements, standards,
terms and conditions (including services) set forth in Exhibit B ("Quality
Exhibit") and incorporated into this Agreement as if fully set forth herein.
Such Exhibit B may be revised from time to time upon mutual agreement of the
parties.

1.20  "REGULATORY AGENCIES" shall mean FDA, EMEA, MHW and the relevant
equivalent foreign regulatory agencies (including, without limitation, the
Health Protection Branch in Canada ("HPB") and the Therapeutic Goods
Administration in Australia ("TGA").

1.21  ***

1.22  "SUPPLIED THIRD PARTY" shall mean Sanofi-Synthelabo and its Affiliates as
long as (i) the Agreement dated May 13, 1997 between Sanofi-Synthelabo and
Praecis remains in effect, or (ii) an agreement is entered into between Amgen
and Sanofi-Synthelabo regarding the supply of API to Sanofi-Synthelabo which
replaces the supply obligations in the Sanofi-Synthelabo/Praecis agreement, and
then so long as such Amgen/Sanofi-Synthelabo agreement remains in effect.

1.23  "SUPPLY SCHEDULE" shall mean the Supply Schedule set forth on Exhibit A
attached hereto and incorporated herein, identifying the schedule for purchase
orders of API and the price for such API.

1.24  "SPECIFICATIONS" shall mean the requirements, tests and standards
contained in the relevant exhibits attached hereto as follows: for API
Manufactured using *** Synthesis, the Specifications shall consist of Exhibit C,
Section I (the "*** SYNTHESIS SPECIFICATIONS") ***

1.25  "UCB TECHNICAL INFORMATION" shall mean any and all know-how, trade
secrets, formulations, process, vendor or supplier information, raw material,
peptide or intermediate specifications, methods and the like, whether or not
patented or patentable, including without limitation, pre-clinical,
pharmacological, toxicological, chemical, physical and analytical, safety and
quality control or other proprietary data and information relating to the
development, testing, use, manufacture or marketing of peptides (including the
API) which UCB or any of its Affiliates has now (which is fully set forth in the
Description of *** Synthesis in Exhibit C, Section II, *** with respect to the
UCB Manufacture of API) or may conceive, develop, acquire or have the ability to

                                        4
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

license or sublicense (under licenses from others or otherwise) during the term
of or in performance of this Agreement, provided that any of the foregoing
(including that set forth in Section II of Exhibit C or D) which would otherwise
constitute UCB Technical Information (i) shall not be deemed to be UCB Technical
Information unless it constitutes Confidential Information and (ii) shall not be
deemed to be UCB Technical Information, but rather Other IP (as defined in
Section 6.3 below), to the extent that it was jointly conceived, discovered or
developed by Amgen or its Affiliates and UCB or its Affiliates.

1.26  "USP" shall mean United States Pharmacopoeia as in effect from time to
time.

                                   ARTICLE TWO
                    REPRESENTATIONS, WARRANTIES AND COVENANTS

2.1   AMGEN REPRESENTATIONS AND WARRANTIES AND COVENANTS.

      (a) CORPORATE POWER. As of the Effective Date, Amgen is duly organized and
validly existing under the laws of Delaware and has full corporate power and
authority to enter into this Agreement and to carry out the provisions hereof.

      (b) DUE AUTHORIZATION. As of the Effective Date, Amgen is duly authorized
to execute and deliver this Agreement and to perform its obligations hereunder.
The person executing this Agreement on Amgen's behalf has been duly authorized
to do so by all requisite corporate action

      (c) BINDING AGREEMENT. This Agreement is a legal and valid obligation
binding upon Amgen and enforceable in accordance with its terms. As of the
Effective Date, the execution, delivery and performance of this Agreement by
Amgen does not conflict with any agreement, instrument or understanding, oral or
written, to which it is a party or by which it may be bound, nor violate any
material law or regulation of any court, governmental body or administrative or
other agency having jurisdiction over it.

      (d) VALIDITY. As of the Effective Date, Amgen is aware of no action, suit
or inquiry or investigation instituted by any federal or state governmental
agency which questions or threatens the validity of this Agreement.

2.2   UCB REPRESENTATIONS AND  WARRANTIES AND COVENANTS

      (a) CORPORATE POWER. As of the Effective Date, Amgen is duly organized and
validly existing under the laws of Delaware and has full corporate power and
authority to enter into this Agreement and to carry out the provisions hereof.

      (b) DUE AUTHORIZATION. As of the Effective Date, Amgen is duly authorized
to execute and deliver this Agreement and to perform its obligations hereunder.
The person

                                        5
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

executing this Agreement on Amgen's behalf has been duly authorized to do so by
all requisite corporate action.

      (c) BINDING AGREEMENT. This Agreement is a legal and valid obligation
binding upon Amgen and enforceable in accordance with its terms. As of the
Effective Date, the execution, delivery and performance of this Agreement by
Amgen does not conflict with any agreement, instrument or understanding, oral or
written, to which it is a party or by which it may be bound, nor violate any
material law or regulation of any court, governmental body or administrative or
other agency having jurisdiction over it.

      (d) VALIDITY. As of the Effective Date, Amgen is aware of no action, suit
or inquiry or investigation instituted by any federal or state governmental
agency which questions or threatens the validity of this Agreement.

      (e) COMPLIANCE. UCB covenants that (i) it will use its best efforts, using
no less than commonly accepted professional standards of workmanship, as
practiced in the relevant industry, to accomplish the goals and objectives of
this Agreement, (ii) the API will be Manufactured in accordance with the
Specifications and the Quality Exhibit and in compliance with standard industry
practice, Regulatory Agencies' guidelines, USP, EP, JP and all applicable
federal, state and local laws and regulations including without limitation cGMPs
(as required by the Agreement) and all applicable laws and regulations of
Belgium and the European Union and (iii) UCB will not utilize any process or
materials in manufacturing the API *** that to UCB's knowledge would infringe
any issued patent or other intellectual property rights, including, but not
limited to, published patent applications in the United States, European Union
and Japan, of a third party without Amgen's prior written consent.

      (f) ADEQUATE PREMISES AND PERSONNEL. UCB has adequate premises and
equipment, knowledge and experience and competent personnel to Manufacture the
API in accordance with the Specifications and the terms and conditions set forth
in this Agreement.

      (g) THIRD PARTIES. UCB will not subcontract or otherwise transfer
responsibility for any supply or development services to be provided to Amgen
hereunder without Amgen's prior written consent.

      (h) OWNERSHIP OF INTELLECTUAL PROPERTY. UCB represents and warrants to
Amgen that (i) it is the sole and exclusive owner or the UCB Technical
Information and that it has the full right, power and authority to grant the
licenses to Amgen pursuant to Article Six below and (ii) that the grant of such
licenses and UCB's performance of its obligations hereunder (including its use
of the UCB Technical Information in connection with such performance) do not and
will not, to the best of UCB's knowledge, violate or infringe upon the
intellectual property or other rights of any third party.

                                        6
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                  ARTICLE THREE
                                   DEVELOPMENT

3.1   COMPLETION OF DEVELOPMENT OF *** SYNTHESIS.

      (a) Pursuant to the terms of the Praecis-UCB Agreement, UCB has
established a process for the assembly, synthesis and purification of the API
according to the specifications established by Praecis attached hereto as
Exhibit C, Section I (" *** Synthesis Specifications"). This *** Synthesis
process is described in Exhibit C, Section II (the " *** Synthesis"). In
connection with the *** Synthesis, UCB has prepared all relevant data and
information for the CMC, developed the analytical procedures and supplied
stability batches and validation batches, all in accordance with the plan agreed
upon by Praecis and UCB (the " *** Synthesis Development Plan"). An outline of
the *** Synthesis Development Plan developed by Praecis and UCB is attached
hereto as Exhibit C, Section III. The *** Synthesis Development Plan may be
amended or updated from time to time by written agreement of the Parties, as
development proceeds and results are obtained. In addition, UCB, with the
cooperation of Amgen and/or Praecis as necessary, will, with diligent pursuit,
support development and registration and filing activities for rework and/or
recovery procedures. Amgen and its Affiliates shall have the right to review any
manufacturing and regulatory documents under the confidentiality obligations
contained in this Agreement.

      (b) In connection with the complete development of the *** Synthesis,
Amgen agrees to pay UCB a total of *** US Dollars (USD$***), covering all
development costs including without limitation research, industrial, process,
scale-up, validation, regulatory and documentation. Such payment is to be spread
out evenly among the *** kg of API to be ordered by Amgen pursuant to Purchase
Orders #4, #5 and #6 described in the Supply Schedule attached as Exhibit A. As
a result, the effective price per kilogram for Purchase Orders #4, #5 and #6
will increase from $***/kg to $***/kg. The parties acknowledge that the payment
contemplated in this section (b) is, INTER ALIA, consideration for the license
rights to the *** Synthesis acquired by Amgen in Section 6.4(b) below.

3.2   ***

      (a) ***

      (b) ***

      (c) ***

      (d) ***

      ***

      ***

      (e) ***

      (f) ***
                                        7
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

3.3   AMGEN PROCESS IMPROVEMENTS. The parties acknowledge that Amgen is
developing processes related to the manufacture of API, concentrating primarily
on the areas of *** and other aspects of the manufacture in addition to the ***
stages (collectively "Amgen Process Improvements"). These Amgen Process
Improvements may be applicable to API Manufactured using the *** Synthesis ***.
If Amgen develops Amgen Process Improvements that Amgen would like to have
incorporated into the Manufacture of API, Amgen will provide such Amgen Process
Improvements to UCB, along with the necessary assistance to implement the Amgen
Process Improvements. At Amgen's request, UCB will use its best efforts to
incorporate the Amgen Process Improvements into the Manufacture of API,
consistent with the other terms and conditions of this Agreement. Amgen Process
Improvements shall be Confidential Information of Amgen.

3.4   DOCUMENTATION OF DEVELOPMENT EFFORT. UCB shall maintain documentation of
all development activities (*** to the extent reasonably requested by Amgen, the
*** Synthesis) in English in sufficient detail to establish an appropriate
record for use in regulatory filings and to document performance of its
obligations under this Agreement. In addition, UCB shall maintain a "Development
History Report" which shall contain written facts and information of the
development of the *** Synthesis. Such Development History Report shall include,
at a minimum, experiments conducted, justifications and explanations for
synthesis routes adopted, analytical methods and data, and material
specifications.

3.5   MATERIALS AND EQUIPMENT. All materials and equipment necessary for the
development and production of API will be provided by UCB. UCB shall be solely
responsible for all capital costs associated with expanding UCB's Manufacturing
capacity, as necessary to comply with UCB's supply obligations under this
Agreement.

3.6   EXCLUSIVITY. During the term of this Agreement, UCB shall work exclusively
with Amgen in developing manufacturing processes for API, and will not develop
manufacturing processes for API for any third party and shall not manufacture
for any third party any peptides or other compounds which exhibit Lutenizing
Hormone Releasing Hormone (LHRH) antagonist activity. During the Agreement and
for a period of *** following termination of this Agreement, UCB shall not use
any Amgen Confidential Information in the manufacture of any *** for any third
party.

                                  ARTICLE FOUR
                                     SUPPLY

4.1   AUTHORIZED REPRESENTATIVES

                                        8
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

      (a) Exhibit F lists the Amgen representatives authorized to act on Amgen's
      behalf during interactions with UCB pursuant to this Agreement and the UCB
      representatives authorized to act on UCB's behalf during interactions with
      Amgen pursuant to this Agreement.

      (b) The Amgen Contract Manufacturing representative(s) set forth on
      Exhibit F are the sole authorized Amgen representatives for delivering
      requests for API, production information and scheduling information
      ("Production Information"). The Amgen Corporate Quality Assurance
      representative shall be the sole authorized Amgen representative for
      quality issues. The UCB Contract Manufacturing representative(s) set forth
      on Exhibit F are the sole authorized UCB representatives with respect to
      Production Information. The UCB Quality Assurance representative shall be
      the sole authorized UCB representative for quality issues. The UCB
      Regulatory Affairs representative shall be the sole authorized UCB
      representative for regulatory issues.

      (c) Any Production Information which does not originate from an authorized
      Contract Manufacturing representative is for information only and
      non-binding.

      (d) UCB will deliver all invoices hereunder to the Amgen Contract
      Manufacturing representative for approval.

      (e) Either party may modify Exhibit F (as it applies to their own
      authorized representatives) from time to time, by giving written notice of
      such modification to the other party.

4.2   PRODUCT FORECAST ESTIMATES.

      (a) SUPPLY REQUIREMENTS. Subject to the terms and conditions of this
      Agreement, UCB shall manufacture and supply to Amgen and Amgen shall
      purchase from UCB the full amount of API ordered by Amgen pursuant to this
      Agreement. Except as specifically provided herein, Amgen shall have no
      obligation to purchase a minimum quantity of API from UCB.

          (i)  YEAR 2000 AND 2001. The Supply Schedule, attached hereto as
      Exhibit A and incorporated herein, sets forth Amgen's anticipated
      requirements of API from UCB for the calendar year 2000 and 2001. These
      amounts are firm subject to the conditions contained in Exhibit A.

          (ii) COMMERCIAL SUPPLY: YEAR 2002 AND BEYOND. Prior to commercial
      launch of the Product, Amgen will supply *** forecasts to UCB containing
      its requirements for supply of API from UCB. *** prior to the anticipated
      date of first commercial sale of Finished Product in the United States and
      by the *** thereafter, Amgen will be required to provide UCB with a
      written *** estimate of Amgen's requirements for API from UCB. Each
      forecast shall cover estimated

                                        9
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

      supply for the *** period commencing *** after the forecast is given. With
      respect to these forecasts, the *** of this *** schedule will be binding
      upon Amgen. The *** of this *** schedule will be also be binding upon UCB
      plus *** percent (+ ***%) and UCB commits to make the Facility and
      appropriate UCB personnel available in order to comply with the estimate.
      UCB will use its reasonable efforts, but will be under no obligation, to
      supply API in excess of ***% above the estimate.

      (b) MANUFACTURING PROCESS. Unless otherwise specified by Amgen, all API to
      be supplied by UCB pursuant to this Agreement shall be Manufactured using
      the *** Synthesis. ***. UCB shall be solely responsible for all capital
      costs and all other costs associated with expanding UCB's capacity for
      Manufacturing API using either the *** Synthesis *** to meet UCB's supply
      requirements under this Agreement.

      (c) CHANGES. Upon the written request of Amgen, UCB shall implement any
      modifications related to the Manufacture of API requested by Amgen after
      the Effective Date, including, but not limited to, those which in Amgen's
      opinion are necessitated by a change after the Effective Date in any law
      or regulation (including those of the US and EU cGMPs) or applicable
      standards or Specifications referenced herein. Costs associated with the
      implementation of any changes necessitated by law or regulation shall be
      borne by UCB. Costs associated with the implementation of any changes
      necessitated by change in the standards or Specifications instigated by
      Amgen shall be borne by Amgen. Amgen shall reimburse UCB for such changes
      at UCB's cost.

      (d) BATCH SIZE. Each Batch of API delivered to Amgen pursuant to this
      Agreement shall be *** kilograms, net peptide weight, plus or minus ***
      kilogram (***kg +/- 0.***kg). UCB shall request Amgen's prior written
      approval (which shall not be unreasonably withheld) if smaller batches are
      to be delivered to Amgen. All references to the weight of API in this
      Agreement or any exhibit hereto shall mean net peptide weight as
      determined by the Specifications.

4.3   MANUFACTURING SCHEDULE. UCB will provide Amgen with a proposed
      Manufacturing schedule for (i) any API covered by Purchase Orders #4, #5,
      #6 and #7, as soon as practicable after execution of this Agreement (with
      the Manufacturing schedule for Purchase Orders #6 and #7 based on
      assumptions as to when the Purchase Order shall be placed), (ii) the
      supply of API requested for the *** of Amgen's *** estimate within *** of
      receipt of the estimate and (iii) for any amounts with respect to which
      Amgen shall have submitted a Purchase Order as set forth in Section 4.4
      below within *** of receipt of the Purchase Order. The proposed
      Manufacturing schedule shall include when the Manufacture will be
      undertaken and the date by which API will be shipped to Amgen. The parties
      shall promptly finalize the Manufacturing schedule upon receipt by Amgen.
      In addition, UCB shall provide to Amgen, on a weekly basis, an updated

                                       10
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

      manufacturing and delivery schedule for API on order. The information in
      such schedule shall include lot numbers, quantities, peptide weight,
      manufacturing status, QC status, delivery date and invoice number. UCB
      agrees to exercise its best efforts to meet the Manufacturing schedule as
      agreed between the parties.

4.4   PURCHASE ORDERS. Except as otherwise specified in the schedule for supply
      of API as set forth in Exhibit A (the "Supply Schedule") Amgen shall place
      purchase orders, upon the terms mutually agreed upon, with UCB at least
      *** prior to the requested delivery date in such purchase order and UCB
      shall promptly accept such orders in writing. The terms of this Agreement
      shall govern any such purchase order and in the event a purchase order
      shall include terms beyond API, quantity and date for manufacturing and
      delivery, none of such other terms will be enforceable. UCB shall use its
      best efforts to accommodate Amgen's scheduling requirements taking into
      due account its own scheduling requirements. UCB will use its best efforts
      to accommodate Amgen's request to amend a purchase order to increase or
      decrease the amount of API to be supplied, provided that if Amgen requests
      reduced production less than *** prior to the beginning of the
      Manufacturing process, then UCB shall not be obliged to comply unless it
      can reasonably schedule replacement production with product which had not
      already been scheduled for production.

4.5   MATERIALS. UCB shall be responsible for the procurement of and payment for
      all materials and equipment needed for the Manufacture of API. UCB shall
      in good faith consider having dual suppliers for materials needed for such
      Manufacture.

4.6   PROCESSING.

      (a) SPECIFICATIONS AND APPLICABLE LAW. UCB warrants that all Manufacturing
      shall be performed in accordance with, and that the API shall meet, the
      Specifications, the Quality Exhibit and all applicable laws and
      regulations, including without limitation, cGMPs and all applicable laws
      and regulations of Belgium and the European Union. Before, during and
      after the Manufacture of each Batch, UCB shall, with respect to such
      Batch, obtain samples, monitor the Manufacturing process and environment
      and keep such records as all of the foregoing are required by the
      Specifications, the Quality Exhibit and/or Batch Records.

      (b) MAINTENANCE OF HEALTH STANDARDS. UCB shall be solely responsible for
      adherence to appropriate health standards for its employees and
      furthermore will operate under guidelines provided by the Material Safety
      Data Sheet as updated from time to time (attached hereto as Exhibit G).

4.7   STORAGE, HANDLING, SHIPMENT.

                                       11
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

      (a) STORAGE. UCB shall store and handle all materials used in Manufacture
      and all API as required by the Specifications, the Quality Exhibit and/or
      applicable cGMP requirements. In addition, UCB shall take such actions as
      are reasonably necessary to protect such materials from damage and
      deterioration, and to protect employees from exposure as required by the
      Material Safety Data Sheet.

      (b) SHIPMENT. Upon UCB's and Amgen's Quality Assurance written release of
      an API Batch, UCB shall promptly ship the Batch to Amgen (or other
      locations reasonably designated by Amgen), or, at Amgen's discretion,
      warehouse the completed API for a maximum of sixty (60) days at no cost to
      Amgen, and thereafter at charges to be mutually agreed upon, to the extent
      warehousing space is available.

      (c) RISK OF LOSS. Risk of loss for all API rests with UCB until delivery
      of such API to Amgen pursuant to subsection (d) below.

      (d) PRODUCT DELIVERY. API ordered hereunder shall be delivered by UCB Ex
      Works Braine-L'Alleud, express courier selected by Amgen (ICC Incoterms
      2000).

4.8   CREDITS UPON REJECTION OF BATCH.

      Should Amgen reject any Batch pursuant to Section 9 of the Quality Exhibit
      set forth in Exhibit B (the "Quality Exhibit") and UCB shall agree that
      such rejection was justified, UCB shall promptly credit Amgen's account
      for the amount paid pursuant to Section 4.9 below for the rejected API, or
      at Amgen's option, supply replacement API, at no additional cost to Amgen,
      on a priority basis, as mutually agreed to by both parties. Should Amgen
      reject any Batch pursuant to this Section and should UCB, after good faith
      negotiation, fail to agree that such rejection was justified, the parties
      shall mutually agree, such agreement not to be unreasonably withheld, upon
      a third party to test samples of such Batch and to review records and test
      data and other relevant information developed by both parties relating
      thereto to ascertain liability for the breach. The findings of such third
      party shall be binding on both parties. If Amgen is found liable, Amgen
      shall pay the costs of such tests and shall be deemed to have accepted the
      affected Batch. If UCB is found liable, UCB shall pay the costs of such
      tests and shall promptly credit Amgen's account for the price paid by
      Amgen pursuant to Section 4.9 for the API, or at Amgen's option,
      Manufacture replacement API, at no additional cost to Amgen, on a priority
      basis, as mutually agreed to by both parties. Notwithstanding anything to
      the contrary stated in this Section, if Amgen and UCB are found to be
      comparatively at fault, each shall pay the costs of such tests and the
      price of the API according to the percentage of the respective Party's
      fault.

4.9   PAYMENT AND INVOICES. Amgen shall pay UCB a price for API at the rates set
      forth in Exhibit A. Transfer of an API Batch will be considered complete
      for

                                       12
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

      invoicing purposes when an API Batch has been released by Amgen. All
      prices referred to on Exhibit A are exclusive of any taxes and duties,
      such as sales, export, import, value added tax, and excise duty, which
      shall be added to such prices as appropriate. All invoices for supply of
      API accruing hereunder shall be delivered to the Amgen Contract
      Manufacturing Representative, as provided in Exhibit F. Invoices shall be
      submitted to Amgen only after UCB's Quality Assurance release of the API
      Batch. Payment shall be made in U.S. Dollars net sixty (60) days from
      receipt of the invoice, ***.

                                  ARTICLE FIVE
                                 INDEMNIFICATION

5.1   INDEMNIFICATION BY AMGEN.

      (a) Amgen agrees to indemnify, defend and hold harmless UCB, its
Affiliates and their officers, directors, agents and employees, from and against
all costs, claims, suits, expenses (including attorneys' fees) and damages
arising out of or resulting from the use, sale and/or distribution of any API
unless such costs, claims, suits, expenses or damages result from the negligence
or willful misconduct of UCB.

      (b) Amgen agrees to indemnify, defend and hold harmless UCB, its
Affiliates and their officers, directors, agents and employees, from and against
all costs, claims, suits, expenses (including attorneys' fees) and damages
arising out of or resulting from a material breach by Amgen of any
representation, warranty or obligation under this Agreement, subject to any
limitations set forth in this Agreement.

      (c) Amgen will defend at its expense any claim brought against UCB, its
Affiliates and their officers, directors, agents and employees to the extent
based on a claim that any API manufactured by UCB infringes a valid and
enforceable third party patent, except to the extent such claim is based on or
arises out of the Manufacturing process utilized by UCB. Amgen will indemnify
the above entities and persons for any expenses incurred and directly
attributable to any such claim but only on the condition that:

          (i)   Amgen is promptly notified in writing of any such claim;

          (ii)  Amgen shall have sole control of the defense of such claim;

          (iii) UCB gives Amgen reasonable information and assistance for such
defense at Amgen's cost.

      The foregoing states Amgen's entire liability concerning infringement with
respect to API.

                                       13
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

5.2   INDEMNIFICATION BY UCB.

      (a) UCB shall indemnify, defend and hold harmless Amgen, its Affiliates
and their officers, directors, agents and employees, from and against all costs,
claims, suits, expenses (including attorneys' fees) and damages arising out of
or resulting from UCB's negligence or intentional misconduct in performing the
services contemplated under this Agreement.

      (b) UCB agrees to indemnify, defend and hold harmless Amgen, its
Affiliates and their officers, directors, agents and employees, from and against
all costs, claims, suits, expenses (including attorneys' fees) and damages
arising our of or resulting from a material breach by UCB of any representation,
warranty or obligation under this Agreement, subject to any limitations set
forth in this Agreement.

      (c) UCB will defend at its expense any claim brought against Amgen, its
Affiliates and their officers, directors, agents and employees to the extent
based on a claim that the Manufacturing process utilized by UCB to Manufacture
API infringes a valid and enforceable third party patent. UCB will indemnify the
above entities and persons for any expenses incurred and directly attributable
to any such claim but only on the condition that:

          (i)   UCB is promptly notified in writing of any such claim;

          (ii)  UCB shall have sole control of the defense of such claim;

          (iii) Amgen gives UCB reasonable information and assistance for such
defense at UCB's cost.

      The foregoing states UCB's entire liability concerning infringement with
respect to Manufacture of the API.

5.3   LIMITATION ON LIABILITY. Neither party shall be liable to the other for
indirect, incidental or consequential damages arising out of any terms or
conditions in this Agreement or with respect to the performance thereto.

5.4   INSURANCE

      (a) BY UCB. UCB shall maintain comprehensive general liability insurance,
including contractual liability insurance, against claims for bodily injury or
property damage arising out of its activities contemplated by this Agreement,
with such insurance companies and in such amounts as UCB customarily maintains
for similar activities. UCB shall maintain such insurance during the term of
this Agreement and thereafter for so long as UCB maintains comprehensive general
liability insurance for itself. UCB may self-insure if that is customary for UCB
in similar situations.

      (b) BY AMGEN. Amgen shall maintain comprehensive general liability
insurance, including contractual liability insurance, against claims for bodily
injury or property damage arising out of its activities contemplated by this
Agreement, with such insurance companies and in such amounts as Amgen
customarily maintains for similar activities. Amgen shall maintain such
insurance during the term of this Agreement and thereafter for

                                       14
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

so long as Amgen maintains comprehensive general liability insurance for itself.
Amgen may self-insure if that is customary for Amgen in similar situations.

                                   ARTICLE SIX
                              INTELLECTUAL PROPERTY

6.1   UCB INTELLECTUAL PROPERTY. The Parties hereby acknowledge that UCB is the
exclusive owner of all UCB Technical Information.

6.2   AMGEN INTELLECTUAL PROPERTY. The Parties hereby acknowledge and agree that
(i) Praecis exclusively owns (and has licensed to Amgen) all intellectual
property and/or know-how related to the API in existence as of the effective
date of the UCB-Praecis Agreement (March 12, 1998) ("Praecis Original
Intellectual Property") and (ii) Amgen shall exclusively own all intellectual
property and/or know-how arising during the development of the *** Synthesis
which specifically relate to the API ("Amgen Development Intellectual Property")
and (iii) Amgen shall exclusively own all intellectual property and know-how
related to Amgen Process Improvements (as defined in Section 3.3 above). The
Praecis Original Intellectual Property, the Amgen Development Intellectual
Property and the Amgen Process Improvements shall, collectively, be referred to
as "Amgen Intellectual Property" for purposes of this Agreement. UCB shall
promptly disclose to Amgen all Amgen Development Intellectual Property that may
arise during UCB's performance of this Agreement and shall assist Amgen in the
preparation of all documents necessary to effectuate Amgen's rights in such
Amgen Development Intellectual Property.

6.3   OTHER INTELLECTUAL PROPERTY. Any intellectual property and/or know-how
developed during the term of this Agreement that is neither UCB Technical
Information nor Amgen Intellectual Property as defined above shall be subject to
the provisions of this section ("Other IP"). The parties agree that such Other
IP shall belong to UCB to the extent that it was solely developed by UCB and to
Amgen to the extent it was solely developed by Amgen. If jointly developed, such
Other IP shall belong to UCB to the extent that the parties agree that the major
significance of the Other IP lies primarily within the scope of UCB's primary
business interests and such Other IP shall belong to Amgen to the extent that
the parties agree that the major significance of the Other IP lies primarily
within the scope of Amgen's primary business interests; if the parties disagree,
the Other IP shall belong to that party which the parties agree was most
responsible for development of the Other IP. Such determination of ownership is
to be made on a case by case basis by the Amgen Authorized Representatives and
the UCB Authorized Representatives, taking into consideration the factors
identified above, with each party acting in good faith to make such a
determination within a reasonable time frame. If the parties are unable to reach
a consensus within a reasonable timeframe, the parties agree to have an
independent third party jointly selected by the parties determine to whom the
Other IP shall belong, based on the factors identified above. Subject to the
restrictions

                                       15
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

identified in Section 6.4 below, each party agrees to grant and hereby grants to
the other party a non-exclusive, royalty-free, irrevocable, world-wide license
(with right to sublicense) to any Other IP which it owns by virtue of this
Section 6.3. UCB shall promptly disclose to Amgen any Other IP and the Parties
shall cooperate with and assist each other in the preparation of all documents
necessary to effectuate the appropriate Party's rights in such Other IP.

6.4   RIGHTS TO INTELLECTUAL PROPERTY.

      (a) ***.

      (b) *** SYNTHESIS. The parties agree and acknowledge that, notwithstanding
any language to the contrary herein, Amgen, in exchange for, INTER ALIA, the
consideration paid in Section 3.1 above, has acquired an exclusive, perpetual,
irrevocable royalty-free license with right to grant sublicenses to all UCB
Technical Information and/or Other IP necessary to use the *** Synthesis in the
manufacture and development of API. UCB agrees, upon request by Amgen, to
promptly transfer to Amgen all information, without limitation, related to, or
reasonably required to perform, the *** Synthesis (including without limitation
the current Drug Master File, the SOP's and any master Batch Records), and, at
Amgen's cost (to be reasonably determined by the Parties), to provide technical
assistance to Amgen as reasonably necessary for Amgen or a third party selected
by Amgen to perform the *** Synthesis; provided, however, UCB shall not be
required to provide technical assistance to any third party to the extent such
third party is a direct competitor of UCB in the development and production of
pharmaceutical-grade bulk peptides. Such license includes, without limitation,
(i) the right to use or incorporate quantities of API supplied by UCB in
connection with the manufacture, use or sale of Finished Product and/or in
connection with the manufacture, use or sale of materials to be used in clinical
trials and (ii) the right to make or have made quantities of API using the
licensed information in connection with the manufacture, use or sale of Finished
Product and/or in connection with the manufacture, use or sale of materials to
be used in clinical trials.

6.5   GRANT-BACK LICENSE. Amgen hereby grants to UCB and its Affiliates (i)
during the term of this Agreement, a non-exclusive royalty-free license to use
any Amgen Intellectual Property or Other IP owned by Amgen solely to make API
for Amgen; (ii) during the term of this Agreement and thereafter, a perpetual,
irrevocable, non-exclusive royalty-free license, with right to grant sub-license
to use such Amgen Intellectual Property or Other IP owned by Amgen solely to
make and have made peptides other than API and other than any other compound
which exhibits Lutenizing Hormone Releasing Hormone (LHRH) antagonist activity
and/or LHRH agonist activity.

                                  ARTICLE SEVEN
                            CONFIDENTIAL INFORMATION

                                       16
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

7.1   NONDISCLOSURE AND NON-USE OF CONFIDENTIAL INFORMATION. Except to the
extent expressly authorized by this Agreement, during the term of this Agreement
and for ten (10) years after the expiration or termination of this Agreement,
neither Party shall (i) disclose, publish or make available any Confidential
Information disclosed to it by the other to any third party, including employees
who do not need to know or have access to such Confidential Information and/or
(ii) transfer or otherwise use or exploit any such Confidential Information for
any purpose.

7.2   THREE-WAY CONFIDENTIAL DISCLOSURE AGREEMENT. The parties agree to remain
bound by the terms of the Confidential Disclosure Agreement executed May 25,
2000 by and among Praecis, Amgen and UCB ("Three-Way CDA"). To the extent the
terms of this Agreement conflict with the Three-Way CDA, this Agreement shall
govern; to the extent the terms are not in conflict, both this Agreement and the
Three Way CDA shall be operable.

7.3   ANNOUNCEMENTS. During the term of this Agreement, neither Party shall make
any press release or other disclosure of the existence or terms of this
Agreement without the prior written consent of the other Party, except as
required by a court of competent jurisdiction or pursuant to the disclosure
requirements of U.S. federal or state or other regulatory agencies, including
the Securities and Exchange Commission.

                                  ARTICLE EIGHT
                              TERM AND TERMINATION

8.1   TERM. Unless terminated in accordance with its terms, this Agreement will
remain in full force and effect until December 31, 2008, except that it shall be
automatically renewed for consecutive two (2) year periods, unless terminated by
either party by written notice given at the latest twenty-four (24) months
before the expiration of the initial period or any renewal period.

8.2   TERMINATION.

      (a) REGULATORY APPROVAL/AUDIT. Amgen may, in its sole discretion,
terminate this Agreement upon notice to UCB in the event that (i) Amgen shall be
unable to obtain Regulatory Agency approval to have UCB manufacture API for
commercial use at the Facility by June 30, 2003; or (ii) if as a result of an
audit by Amgen, it is deemed by Amgen that UCB fails to comply with cGMPs. Prior
to terminating pursuant to subsection (ii), Amgen shall notify UCB of its
determination and give UCB ninety (90) days to correct any insufficiencies. If
at the end of such ninety days, UCB still fails to comply with cGMPs, then Amgen
may immediately terminate this Agreement.

                                       17
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

      (b) DEFAULT. Either Party may terminate this Agreement upon written notice
to the other if (i) any representation or warranty of the other Party shall have
been untrue in any material respect when made, or (ii) the other Party shall
fail to perform any material obligation set forth herein which failure shall not
be cured within thirty (30) days following receipt of notice from the
nonbreaching Party setting forth the nature of the default and demanding that
the default be cured.

      (c) BANKRUPTCY. Either Party may terminate this Agreement, effective
immediately upon the giving of written notice to the other Party, if the other
Party shall file a petition for bankruptcy, or shall be adjudicated as bankrupt,
or shall take advantage of any applicable insolvency laws, or shall make an
assignment for the benefit of creditors, or shall have a receiver, whether
appointed by private instrument or court officer appointed for its property.

      (d) BY AMGEN FOR REJECTION OR FAILURE TO SUPPLY. Amgen may terminate this
Agreement immediately upon giving notice to UCB if (i) Amgen properly rejects
pursuant to the term of this Agreement, two (2) consecutive Batches or four (4)
Batches within a set of six (6) consecutive Batches or (ii) UCB fails to meet
the proposed date of delivery for three (3) consecutive Batches for any reason
other than a Force Majeure. Any notice of termination under this Section shall
be provided by Amgen to UCB within seventy-five (75) days after the event giving
rise to the right to terminate.

8.3   EFFECT OF TERMINATION. The termination of this Agreement shall not operate
to relieve UCB of its obligation to complete Manufacture of API ordered by Amgen
prior to the date of notice of termination, unless such termination is effected
as a result of a breach of this Agreement by Amgen, pursuant to Section 8.2(b)
or Amgen's bankruptcy pursuant to Section 8.2(c). Likewise, the termination of
this Agreement shall not operate to relieve Amgen from its obligation to accept
delivery of API and pay for all completed and accepted API ordered by Amgen
prior to the date of notice of termination unless such termination is effected
as a result of a breach of this Agreement by UCB pursuant to Section 8.2(b) or
Section 8.2(d). Except as provided in Section 9.9 below, upon termination of
this Agreement, all of the rights and obligations of the Parties under this
Agreement shall no longer be in effect; provided that unless terminated by UCB
for a breach of this Agreement by Amgen pursuant to Section 8.2(b), all licenses
granted to Amgen to UCB Technical Information and Other IP owned by UCB shall
remain in effect. Upon termination, each party shall promptly return to the
other, at the other's request, any and all Confidential Information of the other
then in its possession or control, except if such information is covered under
surviving license rights.

                                  ARTICLE NINE
                                  MISCELLANEOUS

                                       18
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

9.1   NO WAIVER. Failure of either Party to insist upon strict observance of or
compliance with any of the terms of this Agreement in one or more instances
shall not be deemed to be a waiver of its rights to insist upon such observance
of compliance with the other terms hereon with respect to subsequent failures in
the future.

9.2   NOTICES. All notices and demands required or permitted to be given or made
pursuant to this Agreement shall be in writing and given by certified or
registered mail, postage prepaid and properly addressed, to the address of the
Party to be notified a shown below, or to such other address as to which either
Party may notify the other in writing. Notice shall be effective on the date it
is received.

      If to Amgen:               Amgen Inc.
                                 One Amgen Center Drive
                                 Thousand Oaks, CA 91320-1799
                                 USA

                                 Attn:  Edward Bjurstrom
                                 Vice President, Operations
                                 cc:  Corporate Secretary

      If to UCB:                 UCB S.A.
                                 Chemin du Foriest
                                 B-1420
                                 Braine-l'Alleud, Belgium

                                 Attn: Alain Scarso
                                 General Manager

9.3   ASSIGNMENT. This Agreement shall be binding upon and inure to the benefit
of the Parties, their successors and permitted assigns. Neither Party may assign
this Agreement without the prior written consent of the non-assigning Party,
which shall not be unreasonably withheld. Notwithstanding the foregoing, the
Parties acknowledge and agree that Amgen may assign this Agreement in its
entirety to Praecis upon agreement between Amgen and Praecis.

9.4   GOVERNING LAW AND JURISDICTION. This Agreement is governed by the laws of
the state of New York, U.S.A., without giving effect to that state's choice of
law doctrine. Both parties consent to the exclusive jurisdiction of the courts
of New York, both state and federal.

9.5   FURTHER ACTIONS. The Parties agree to execute, acknowledge and deliver
such further instruments and to do all such other incidental acts as may be
reasonably necessary or appropriate to carry out the purpose and intent of this
Agreement.

                                       19
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

9.6   SEVERABILITY. In the event any one or more of the provisions of this
Agreement should for any reason be held by any court or authority having
jurisdiction over either of the Parties or this Agreement to be invalid, illegal
or unenforceable, such provision or provisions shall be validly reformed so as
to as nearly approximate the intent of the Parties as possible or, if
unreformable, shall be divisible and deleted in such jurisdiction; elsewhere,
this Agreement shall not be affected.

9.7   INDEPENDENT CONTRACTORS. Nothing in this Agreement is intended or shall be
deemed to constitute a partnership, agency, employer-employee or joint venture
relationship between the Parties. All activities by the Parties hereunder shall
be performed by them as independent contractors. Neither Party shall incur any
debts or make any commitments for the other Party, except to the extent
specifically provided herein.

9.8   CAPTIONS. The Parties agree that the headings in the Agreement are used
for the convenience of the Parties only and are not intended to be used in the
interpretation of this Agreement.

9.9   SURVIVAL. The warranties, intellectual property, indemnification and
confidentiality obligations expressly set forth in Article 2, Article 4
Section 6, Article 5, Article 6 and Article 7 shall survive the termination or
expiration of the term of this Agreement.

9.10  AMENDMENTS. The terms of this Agreement shall not be amended or
supplemented except in a written document duly executed by a duly authorized
representative of each Party.

9.11  FORCE MAJEURE. Neither Party shall be responsible to the other, and no
default shall be deemed to have occurred hereunder, for delay in performing any
of its obligations under this Agreement if such delay is caused by or arises
from any strike, stoppage of labor, lockout, inability to obtain any materials
arising out of any action or omission of any third party, breakdown or delays of
carriers or shippers, default by any supplier or sub-contractor, fire, flood,
accident, act of God, any public enemy, governmental or administrative act or
restraint in each case that is unavoidable and beyond the reasonably control of
the affected Party; provided, however, that the Party claiming force majeure
hereunder shall promptly notify the other specifying the cause and probable
duration of the delay.

9.12  UNITED NATIONS CONVENTION. Notwithstanding anything to the contrary
contained in this Agreement, the United Nations Convention on Contracts for the
International Sale of Goods shall have no application to, and shall be of no
force and effect with respect to this Agreement or the matters herein set forth
or contemplated.

9.13  ANTITRUST COMPLIANCE. In the event that any governmental agency of
competent jurisdiction advises either of the parties in writing that one or more
provision of this

                                       20
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

Agreement violates any applicable competition or antitrust law of the United
States, the European Union, Belgium or any other relevant jurisdiction, UCB and
Amgen agree to amend this Agreement to the minimum extent necessary to render it
compatible with such provisions.

9.14  ENTIRE AGREEMENT. This Agreement, including the Exhibits and other
documents provided for herein, sets forth the entire agreement of the Parties
with respect to the subject matter hereof. This Agreement is intended to
supersede and replace in all material respects the UCB-Praecis Agreement, and
the Parties agree to take the necessary steps to terminate the UCB-Praecis
Agreement upon execution of this Agreement.

9.15  COUNTERPARTS. This Agreement may be executed in two or more counterparts,
each of which shall constitute an original, but all of which, when taken
together, shall constitute but one instrument, and shall become effective when
one or more counterparts have been signed by each Party hereto and delivered to
the other Parties.

      IN WITNESS WHEREOF, the Parties have executed this Agreement on the date
first written above, but effective as of the Effective Date.

AMGEN INC.

By: /s/ Edward Bjurstrom
    --------------------
    Edward Bjurstrom
    Vice President, Operations

UCB S.A.

By:  /s/ G. Jacobs      /s/ E. Croufer
     ---------------------------------
      Name:  G. JACOBS  E. CROUFER
             -------------------------
      Title:    (1)        (2)
             -------------------------

      (1) Chairman of the Executive Committee
      (2) Director-General of the Pharma Sector

                                       21
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                    EXHIBIT A
                           SCHEDULE FOR SUPPLY OF API
                               ("SUPPLY SCHEDULE")

A.    YEARS 2000 AND 2001

      1.  BACKGROUND

Pursuant to the UCB-Praecis Agreement, Praecis and UCB had agreed on delivery of
***kg(a) of API through the end of year 2001. Such API was to be delivered
pursuant to three Purchase Orders (the "Initial Purchase Orders"): Purchase
Order #1 for *** kg, placed February 19, 1998; Purchase Order #2 for *** kg,
placed June 30, 1998; and Purchase Order #3 for *** kg, placed June 30, 1998.
The price for all API ordered pursuant to these Initial Purchase Orders was to
be $*** per kilogram. The Parties agree that the Initial Purchase Orders will be
fully enforced to the extent of the first ***kg of API covered thereby; the
Parties further agree, that subject to the terms provided below, the Initial
Purchase Orders to the extent applicable to the remaining ***kg of API will be
canceled and replaced by the new Purchase Orders described below. The first
***kg of API have already been delivered and paid for by Praecis and/or Amgen at
a price of $*** per kilogram. In addition, quantities beyond the initial ***kg
have also been delivered and/or paid for at a price of $*** per kilogram: the
parties acknowledge that to the extent that more than ***kg have been delivered,
invoiced and/or paid for, adjustments will be made as appropriate to account for
the new price (as agreed below) for such API over and above the initial ***kg.
Such adjustments will be made within 30 days of execution of the Agreement.

      2.  NEW PURCHASE ORDERS

Amgen agrees to issue purchase orders and to purchase additional API in the
years 2000 and 2001 as follows:

Year 2000: Amgen will immediately upon execution of this Agreement issue a
purchase order (Purchase Order # 4) for the purchase of *** kg of API at $***(b)
per kilogram, for delivery by year end 2000. Such Purchase Order #4 shall be
firm immediately upon issuance by Amgen.

Year 2001: Amgen will immediately upon execution of this Agreement issue a
purchase order (Purchase Order #5) for the purchase of *** kg of API at $***(b)
per

----------
(a) Note: All references to the weight of API in this Agreement refer to net
peptide weight as determined by the Specifications.
(b) There is $*** in development costs associated with the *** Synthesis that is
being paid from Amgen to UCB, and is being spread out evenly over the *** kgs
being ordered in Purchase Orders #4, #5 and #6, raising the effective price for
those *** kgs from $***/kg to $***/kg. See Section 3.1(b).

                                       22
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

kilogram, for delivery in 2001. Such Purchase Order #5 shall be firm
immediately upon issuance by Amgen.

Year 2001: Immediately upon Amgen's (or an Amgen Affiliate's) filing of an NDA
for Finished Product with FDA (or sooner, in Amgen's sole discretion), Amgen
will issue a purchase order (Purchase Order #6) for *** kg of API at $***(b) per
kilogram, for delivery in 2001. Such Purchase Order #6 shall be firm immediately
upon issuance by Amgen.

NOTE: If Amgen (and/or its Affiliates) decides not to file an NDA for Finished
Product and does not issue Purchase Order #6, the price for the API ordered
under Purchase Order #4 and Purchase Order #5 shall revert to the original price
agreed to between UCB and Praecis, $*** per kilogram, (less $*** in credits
currently owed by UCB), such that Amgen shall pay UCB an additional $*** (61 kg
times $***/kg less $***), and Amgen shall have no obligation to place future
orders. Upon payment of such fee by Amgen, UCB's supply obligations contained
herein shall remain in effect. Upon placement of Purchase Order #6, the prices
for Purchase Order #4 and Purchase Order #5 shall be permanently fixed as
indicated above ($*** per kilogram) and Amgen shall forgive the $*** in credits
currently owed by UCB.

YEAR 2001: Immediately upon UCB's successful completion of its Pre-Approval
Inspection ("PAI") by the FDA (including, without limitation, FDA acceptance of
all UCB's 483 responses), or sooner at Amgen's sole discretion, Amgen will issue
a purchase order (Purchase Order #7) for ***kg of API at $*** per kilogram, for
delivery *** of placement of Purchase Order #7. Purchase Order #7 shall be firm
immediately upon issuance by Amgen.

NOTE: The reference to the year for each of these Purchase Orders is
approximate. It is currently anticipated that the NDA would be filed by year end
2000, resulting in Purchase Order #6 being issued in Q1 2001 and filled in year
2001. Similarly, it is anticipated that the PAI would be completed by end of Q2
2001, and that Purchase Order #7 would be issued and filled in 2001. It is also
anticipated that these two Purchase Orders would cover Amgen's needs through the
end of 2001. All subsequent orders, including without limitation validation
lots, will be subject to the commercial supply prices described in Section B
below. If the occurrence of these events is delayed, it is possible that
Purchase Order #6 or 7 would be filled in 2002. Notwithstanding such a
possibility, all the price and quantity terms contained in Section A and B shall
apply regardless of the timing of such orders.

B.    ONGOING COMMERCIAL SUPPLY:  YEARS 2002 AND LATER

----------
(b) There is $*** in development costs associated with the *** Synthesis that is
being paid from Amgen to UCB, and is being spread out evenly over the *** kgs
being ordered in Purchase Orders #4, #5 and #6, raising the effective price for
those *** kgs from $***/kg to $***/kg. See Section 3.1(b).

                                       23
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

For all API over and above the initial *** kilograms covered by Purchase Orders
4 through 7, the following price shall apply:

<Table>
<Caption>
CUMULATIVE AMOUNT OF API ORDERED    APPLICABLE PRICE*
--------------------------------    -----------------
<S>                                 <C>
First *** kg                        $***/kg
*** kg - *** kg                     $***/kg
*** kg - *** kg                     $***/kg
*** kg - ***kg                      $***/kg
Over *** kg                       < $***/kg
</Table>

All API ordered up to the first *** kg will be billed at a price of $***/kg.
When Amgen has ordered cumulatively more than *** kg over the term of the
Agreement (after the initial *** kg covered by Purchase Orders 4-7), the price
per kilogram for additional orders will drop to $***/kg. Again, when Amgen's
cumulative orders pass ***kg, the price will again drop, this time to $***/kg
for each additional kilogram ordered. At the point at which the cumulative
orders exceed ***kg, the price will drop to $***/kg. After the cumulative orders
exceed ***kg, the Parties will determine an appropriate price at that time, not
to exceed $***/kg.

* - ADJUSTMENTS TO PRICE

The parties intend that in the event any improvements in the process, or
reduction in the cost of raw materials, lead to a reduction in the overall cost
to produce API, the parties will share equitably in such reduced cost to
produce. The parties agree to negotiate in good faith a mechanism for sharing
the cost reduction associated with such events.

                                       24
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                    EXHIBIT B

                  SUPERSEDED IN ITS ENTIRETY BY AMENDMENT NO. 1

                                       25
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                    EXHIBIT C

                                  *** SYNTHESIS

I.    SPECIFICATIONS
II.   DESCRIPTION OF *** SYNTHESIS
III.   *** SYNTHESIS DEVELOPMENT

                                       26
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

EXHIBIT C.I - SPECIFICATIONS

<Table>
<Caption>
[AMGEN LOGO]                          SPECIFICATION
<S>                                          <C>                  <C>            <C>                      <C>
TITLE                                                                            NUMBER                   PAGE
Bulk Drug Substance, ABARELIX (API)                                              S01312                   1 of 3

                                                                                 INITIATOR                EFFECTIVE DATE
                                                                                 M. Marian                07/14/00

OWNER APPROVAL                               DATE                 REGULATORY AFFAIRS APPROVAL             DATE
[illegible signature]                        7        10    00    /s/ Dean M. Waters                      7 /11/00

TECHNICAL EVALUATOR APPROVAL                 DATE                 MANUFACTURING APPROVAL                  DATE
[illegible signature]                        7        11    01    [illegible signature]                   7 /11/00

QUALITY APPROVAL                             DATE                 OTHER APPROVAL                          DATE
[illegible signature]                        7        11    01    N/A
</Table>

1.    DESCRIPTION

      1.1      Acetyl-D-(beta)-naphtylalanyl-D-p-chorophenylalanyl-3-D-
               pyridylalanyl-L-seryl-L-N-methyltyrosyl-D-asparagyl-L-leucyl-L-N
               ((epsilon))-isopropyl-lysyl-L-prolyl-D-alanyl-amide (Abarelix or
               PPI-149).

      1.2      Empirical formula is C72H95N14O14Cl.

2.    SAMPLING REQUIREMENTS

      2.1      Sampling will be performed per contract Manufacturing Procedure.

3.    STORAGE CONDITIONS

      3.1      Store at 2 to 8(Deg.)C in light-proof containers, in a secured
               area.

4.    EXPIRATION DATING

      4.1      See current Expiration Dating Guidelines.

5.    SPECIFICATIONS

               PARAMETER SPECIFICATION               METHOD

      5.1      Appearance                             White to off-white C of A
                                                      powder
      5.2      Identity

      5.2.1    Mass Spectrometry                      Exhibits the proper C of A
                                                      molecular mass

                                       27
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

      5.2.2    HPLC Retention Time            Conforms to standard C of A
               PARAMETER cont'd               SPECIFICATION        METHOD

      5.2.3     Amino Acid Analysis                                C of A
               (Theoretical values)
                5.2.3.1            ***           ***

                5.2.3.2              ***          ***

                5.2.3.3              ***          ***

                5.2.3.4              ***          ***

                5.2.3.5              ***          ***

                5.2.3.6              ***          Conform

      5.3       Peptide Content                ***                 C of A
                by Amino Acid Analysis

      5.4       Related Peptides                                   C of A
                (Impurities)

                5.4.1          Total
                               Impurities      ***

                5.4.2          Individual
                               Impurity        ***

      5.5                  Water Content       ***                 C of A

      5.6       Acetate Content                ***                 C of A

      5.7       Residual Solvents                                  C of A

                5.7.3            ***           ***
                5.7.4             ***          ***
                5.7.5            ***           ***

      5.8       ***                                                C of A

               5.8.1             ***           ***

               5.8.2             ***           ***

               5.8.3             ***           ***

      NOTE: All release test results will be obtained from Manufacturer's
            Certificate of Analysis (C of A).

                                       28
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

[LOGO OF UCB]

EXHIBIT C.II - DESCRIPTION OF *** SYNTHESIS

UCB-BIOPRODUCTS S.A.

                          PRAECIS PHARMACEUTICALS INC.

                           UCB STRATEGY OF SYNTHESIS

1. INTRODUCTION AND OVERVIEW

The manufacturing strategy developed by UCB-Bioproducts for PPI-149 is outlined
in the following chart :

ASSEMBLY BY
                                      ***
                                  [down arrow]
                                       ***
                                  [down arrow]
                                       ***
                                  [down arrow]
                                       ***

***

***.

2.       ***

***

***

                                       29
<Page>
                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

***

3.       ***

***

4.       ***

***

***
***

5.       ***

***
***
6.       ***

***

7.       FLOW CHART

An actual flow chart for a preferred manufacturing strategy is given hereafter,
to illustrate the current process.

(a)   General Flow Chart
(b)   Assembly Flow Chart
(c)   Deprotection Flow Chart
(d)   Purification Flow Chart

                                       30
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

EXHIBIT C.III -  *** SYNTHESIS DEVELOPMENT PLAN

OUTLINE OF UCB DEVELOPMENT/WORK PLAN
PPI-149 DRUG SUBSTANCE

In synergy with PRAECIS/AMGEN :

1.  Develop and Supply both clinical and commercial quantities of PPI-149 Drug
    Substance prepared according to cGMP and other international quality
    standards.
2.  Prepare/assist in preparation of CMC drug substance filings (US NDA Dec.,
    98) European filings estimated 2Q99.
3.  Develop, maintain, and provide documentation to support approval and ongoing
    commercial supply of drug substance.
    -   Batch Production Records
    -   Certificates of Analysis
    -   Development reports
    -   Facilities and instrumentation IQ/OQ/ and PQ
    -   Facilities Drug Master Files, to be included in CMC/DMF
    -   SOP'S
    -   Change control
    -   Validation documentation - strategy, plan, protocol, report
    -   CMC section for NDA filing
    -   Stability programs and reports (development and commercial)
4.  Prepare and qualify reference standards.
5.  Determine and qualify impurity profile including preparation of impurity
    standards as required.
6.  Supply representative pre-launch material.
7.  Source, secure, and qualify appropriate production facilities for commercial
    volumes and expedite scale-up in a timely manner.
8.  Qualify raw material suppliers, dual supply to minimize risk, as
    appropriate.
9.  Outsource qualified intermediates as appropriate.
10. Develop suitable recycle strategy for the filing.
11. Develop/assist in developing a supplemental commercial strategy which
    favorably impacts cycle time and cost of goods.
12. Maintain regulatory filing with appropriate updates (CBE's, AR's).
13. Provide comprehensive regulatory support for international approvals and
    commercializations.
14. Expediently work to correct/improve any findings documented or questions
    generated by regulatory agencies or other quality assessments.

                                       31
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                    EXHIBIT D

                                       ***

                                       32
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                    EXHIBIT E

                  SUPERSEDED IN ITS ENTIRETY BY AMENDMENT NO. 1

                                       33
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                    EXHIBIT F

                  SUPERSEDED IN ITS ENTIRETY BY AMENDMENT NO. 1

                                       34
<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                    EXHIBIT G

                           MATERIAL SAFETY DATA SHEET

    CHEMTREC -Registered Trademark- EMERGENCY TELEPHONE NUMBERS (24 - HOURS)
                           UNITED STATES: 800-424-9300
                      INTERNATIONAL: 202-483-7616 (COLLECT)

 THESE CHEMTREC -Registered Trademark- NUMBERS ARE TO BE USED ONLY IN THE EVENT
        OF A CHEMICAL EMERGENCY INVOLVING A SPILL, LEAK, FIRE, EXPLOSION
                                   OR ACCIDENT

1.  CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRAECIS PHARMACEUTICALS, INC.           GENERAL INFORMATION PHONE NUMBERS:
ONE HAMPSHIRE ST., 5TH FLOOR
CAMBRIDGE, MASSACHUSETTS 02139                   617-494-8400

PRODUCT NAME: abarelix or abarelix Depot or PPI-149
CHEMICAL NAME: Acetyl-D-(beta)-naphthylalanyl-D-p-chlorophenylalanyl-3-pyridyl-
D-alanyl-L-seryl-L-N-methyltyrosyl-D-asparagyl-L-leucyl-L-N((epsilon))-isopropyl
-lysyl-L-prolyl-D-alanyl-amide
THERAPEUTIC CATEGORY: Gonadotropin-releasing hormone antagonist

2.  COMPOSITION/INFORMATION ON INGREDIENTS

<Table>
<Caption>
COMPONENT               CAS REGISTRY    EINECS    PERCENT    MOL. WT.
---------               ------------    ------    -------    --------
<S>                     <C>             <C>       <C>        <C>
abarelix                183552-38-7     -         100%       1416.10
C(72)H(95)N(14)O(14)Cl
</Table>
                     (See Section 8 for exposure guidelines)

3.  HAZARDS IDENTIFICATION

EMERGENCY OVERVIEW:
White powder. May be harmful by inhalation, ingestion, or skin absorption. ***

POTENTIAL HEALTH EFFECTS
***
MEDICAL CONDITIONS ENHANCING TOXICITY: ***

NA = Not Applicable                                                 ND = No data

MSDS No. 002                    ISSUE DATE: 2/24/99                 Page 1 of 6

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

4.  FIRST AID MEASURES

EYE: First check victim for contact lenses and remove if present. Flush victim's
eyes with large quantities of water for at least 15 minutes and contact a
physician if irritation occurs or persists.
SKIN: Flush thoroughly with water for at least 15 minutes while removing all
contaminated clothing. Contact a physician if irritation develops.
INGESTION: Do not give anything by mouth if victim is convulsing or unconscious
and immediately contact a physician. If person is conscious, wash out mouth with
water and contact a physician.
INHALATION: Leave the contaminated area and take deep breaths of fresh air.
Contact a physician.
NOTE TO PHYSICIAN: Treatment is supportive and symptomatic.

5.  FIRE FIGHTING MEASURES

FLAMMABLE PROPERTIES
         FLASH POINT:  NA
         FLAMMABLE LIMITS:
             LOWER FLAMMABLE LIMIT:  NA
             UPPER FLAMMABLE LIMIT:  NA
EXTINGUISHING MEDIA: Use extinguishing media suitable for surrounding materials.
Dust powder is probably combustible.
UNUSUAL FIRE OR EXPLOSION HAZARDS: Organic dusts at sufficient concentrations
can form explosive mixtures with air.
FIRE-FIGHTING INSTRUCTIONS: Firefighters should use self-contained breathing
equipment and full protective clothing.
HAZARDOUS COMBUSTION PRODUCTS: Oxides of carbon and nitrogen, chlorine.

6.  ACCIDENTAL RELEASE MEASURES

SPILLS: Promptly clean up spills using appropriate protective equipment
(respirator, chemical safety goggles, rubber boots, and rubber gloves). Keep
airborne dust to a minimum. Eliminate all ignition sources. Place in a suitable,
properly labeled container for disposal. Wash area with soap and water.
DECONTAMINATION PROCEDURES: Wash area thoroughly with soap and water.

7.  HANDLING AND STORAGE

HANDLING: Avoid contact with eyes, skin and clothing. Do not smell or taste
chemicals. Do not breathe dust. Do not eat, drink, or smoke in areas where
chemicals are present. Wash thoroughly after handling. Wash contaminated
clothing thoroughly before reuse.
STORAGE: Store under cool and dry conditions.

NA = Not Applicable                                                 ND = No data

MSDS No. 002                    ISSUE DATE: 2/24/99                  Page 2 of 6

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

8.  EXPOSURE CONTROLS/PERSONAL PROTECTION

EXPOSURE GUIDELINES: No exposure guidelines established by ACGIH or OSHA.
Manufacturer recommends an occupational exposure limit (OEL) of *** as an 8-hour
time weighted average over a 40-hour work week. The OEL is designed as an
acceptable airborne concentration of a substance for which it is believed that
workers may be repeatedly exposed day after day without adverse health effects.
ENGINEERING CONTROLS: When practicable, handle material in enclosed or contained
processes or with effective local exhaust ventilation. Avoid open handling
without adequate control or containment. The objective of the engineering
control should be to minimize the potential for worker exposure.
RESPIRATORY PROTECTION: Where possible, handle material in enclosed processes or
containers. For operations where exposure to dust is possible, such as weighing
and mixing operations, wear an NIOSH/MSHA-approved full facepiece, powered
air-purifying respirator equipped with a dust/mist filter.
SKIN PROTECTION: Rubber gloves are recommended to minimize potential for skin
contact when handling in dry form or in aqueous solutions. When the material is
dissolved in an organic solvent, wear gloves that provide protection against the
solvent. Wear lab coat or other protective overgarment (e.g., tyvek suit). Base
the choice of protection on the job activity and potential for skin contact.
EYE PROTECTION: Wear safety glasses with side shields, chemical splash guards,
or full face shield, if necessary. Base the choice of protection on the job
activity and potential for contact with eyes or face.

9.  PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE: White to off-white powder
ODOR: Odorless
PHYSICAL STATE: Powder
BOILING POINT: NA
VAPOR PRESSURE: NA
VAPOR DENSITY (AIR = 1): NA
SOLUBILITY IN WATER: ***
SPECIFIC GRAVITY: NA
PH: NA
MELTING POINT: ND
OCTANOL/WATER COEFFICIENT: ND

10. STABILITY AND REACTIVITY

STABILITY: Stable under ordinary storage conditions.
INCOMPATIBILITY: ND
HAZARDOUS DECOMPOSITION PRODUCTS: When heated to decomposition, product may emit
toxic oxides of carbon and nitrogen, chlorine.

NA = Not Applicable                                                 ND = No data

MSDS No. 002                    ISSUE DATE: 2/24/99                  Page 3 of 6

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

HAZARDOUS POLYMERIZATION:  Will not occur.

11. TOXICOLOGICAL INFORMATION

The toxicological properties of this material have not been thoroughly
investigated.

***

PHARMACOLOGY: Abarelix is a polypeptide that functions as a
gonadotropin-releasing hormone antagonist. Gonadotropin-releasing hormone (GnRH)
regulates the synthesis and secretion of FSH and LH, which in turn regulate
plasma levels of estrogen and testosterone. A GnRH antagonist suppresses
gonadotropin secretion and effectively reduces estrogen and testosterone levels.
Adverse side effects will most probably be related to reduced circulating levels
of estrogen and testosterone. Abarelix and abarelix Depot cause a rapid and
reversible suppression of testosterone in man.
DRUG INTERACTIONS: ND.
MEDICAL CONDITIONS ENHANCING TOXICITY: ***

12. ECOLOGICAL INFORMATION

ECOTOXICOLOGICAL INFORMATION: ND
CHEMICAL FATE: ND

13. DISPOSAL CONSIDERATIONS

Dispose of all wastes in an environmentally safe manner, e.g., a chemical
incinerator equipped with an afterburner. If no on-site incinerator is
available, dispose of material in a licensed commercial chemical incinerator if
allowed by the incinerator license or permit. Disposal should be conducted in
accordance with local, state and federal environmental regulations.

14. TRANSPORT INFORMATION

TRANSPORTATION AND HAZARDOUS MATERIALS DESCRIPTION: Not a hazardous material by
DOT.

15. REGULATORY INFORMATION

OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR
1910.1200). Labeling regulated by FDA.
CERCLA/SUPERFUND: Contains no Reportable Quantity (RQ) substances.
SARA SECTION 302: Contains no extremely hazardous substances (EHS).
SARA HAZARD CATEGORY (311/312): Chronic health hazard. Exempted from reporting
since material is regulated by FDA.

NA = Not Applicable                                                 ND = No data

MSDS No. 002                    ISSUE DATE: 2/24/99                  Page 4 of 6

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

SARA 313 INFORMATION: Contains no chemical subject to the reporting requirements
of SARA 313.
TSCA: Drugs exempted from TSCA Chemical Substance Inventory.
CALIFORNIA PROPOSITION 65: Not listed.
EUROPEAN UNION (EU)SYMBOL AND RISK AND SAFETY PHRASES:
Symbol:  T
***

16. OTHER INFORMATION

PACKAGING DESCRIPTION: ND
ADDITIONAL INFORMATION: NA
NFPA RATING:    Health = 1      Fire = 1        Reactivity = 0
REVISIONS/DATE:   2/8/99

                                   DISCLAIMER

The information contained herein is based on data believed to be accurate.
However, no warranty is expressed or implied regarding the accuracy of these
data or the results to be obtained from the use thereof. The publisher, its
parent, subsidiaries and affiliates assume no responsibility for personal injury
or property damage to vendees, users or third parties caused by the material.
Such persons assume all risks associated with the use of the material.

NA = Not Applicable                                                 ND = No data

MSDS No. 002                    ISSUE DATE: 2/24/99                  Page 5 of 6

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                            ASSIGNMENT OF DEVELOPMENT
                         AND SUPPLY AGREEMENT (ABARELIX)

         This Assignment of Development and Supply Agreement (Abarelix) (the
"Assignment"), entered into on the 18th day of January, 2002 (the "Signing
Date"), and effective as of the 17th day of December, 2001 (the "Effective
Date"), is entered into by and between Amgen Inc., located at One Amgen Center
Drive, Thousand Oaks, California 91320-1799 ("Amgen") and PRAECIS
PHARMACEUTICALS INCORPORATED, located at 830 Winter Street, Waltham,
Massachusetts 02451-1420 ("Praecis").

         WHEREAS, effective as of June 21, 2000, Amgen and UCB S.A., a Belgian
corporation with its registered office at Allee de la Recherche 60, B-1070
Brussels, Belgium ("UCB") entered into the Development and Supply Agreement
(Abarelix) for the production and supply of Abarelix API ("Development and
Supply Agreement");

         WHEREAS, Section 9.3 of the Development and Supply Agreement provides
that, upon agreement between Amgen and Praecis, Amgen may assign the Development
and Supply Agreement to Praecis without the consent of UCB;

         WHEREAS, the Amended and Restated Binding Agreement in Principle dated
March 8, 1999 between Amgen and Praecis, along with its amendments
(collectively, the "Agreement in Principle"), requires that in the event of
termination, Amgen shall provide for an orderly and businesslike transfer of
abarelix manufacturing and other related matters to Praecis; and

         WHEREAS, Amgen and Praecis have agreed that Amgen will assign the
Development and Supply Agreement to Praecis as of the Effective Date;

         NOW, THEREFORE, in consideration of the promises and of the mutual
covenants, representations and warranties set forth herein, the parties agree as
follows:

         SECTION 1. DEFINITIONS. Unless otherwise specifically defined herein,
each term used herein which is defined in the Development and Supply Agreement
shall have the meaning assigned to such term in the Development and Supply
Agreement.

         SECTION 2. ASSIGNMENT. As of the Effective Date, Amgen hereby assigns
to Praecis, and Praecis hereby accepts the assignment by Amgen and assumes, all
of Amgen's rights, interests and obligations under the Development and Supply
Agreement. As of the Effective Date, Amgen shall have no further obligation to
Praecis or any third party with respect to manufacturing or supply of Licensed
Product (as such term is defined in the Agreement in Principle).

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

         SECTION 3. NOTICE TO UCB. Concurrent with the execution of this
Assignment, the Parties agree to send UCB notice of the Assignment, in
substantially the form attached hereto as Exhibit A. Praecis hereby affirms and
approves the form of notice to be provided to UCB.

         SECTION 4. INTELLECTUAL PROPERTY. As of the Effective Date, Amgen
hereby grants to Praecis and its affiliates a worldwide, non-exclusive,
royalty-free, perpetual and irrevocable license with the right to grant
sublicenses to use existing Amgen Development Intellectual Property (as defined
in Section 6.2 of the Development and Supply Agreement), Amgen Process
Improvements (as defined in Section 3.3 of the Development and Supply Agreement)
and Other IP owned by Amgen pursuant to Section 6.3 of the Development and
Supply Agreement, solely for the purposes of the manufacture of Licensed
Products (as such term is defined in the Agreement in Principle).

         SECTION 5. MISCELLANEOUS.

A. The parties warrant and represent that they have the right to enter into this
   Assignment. The parties further warrant and represent that the terms of this
   Assignment are not inconsistent with other contractual obligations, express
   or implied, which they may have.

B. This Assignment shall be governed by and interpreted in accordance with the
   laws of the State of California (without regard to its principles of
   conflicts of laws). The parties hereby submit to the jurisdiction of the
   California courts, both state and federal, in all matters concerning this
   Assignment.

C. No modification of this Assignment shall be effective unless made in writing
   and signed by a duly authorized representative of each party.

D. This Assignment constitutes the entire agreement between the parties with
   respect to the Development and Supply Agreement and the transactions
   contemplated therein (the "Subject Matter"), and supersedes all prior
   agreements and understandings between the parties (whether written or oral)
   relating to the Subject Matter.

         IN WITNESS WHEREOF, the parties hereto have caused their duly
authorized representatives to execute this Assignment as of the Effective Date.

AMGEN INC.                                PRAECIS PHARMACEUTICALS
                                          INCORPORATED

BY:   /s/ Fabrizio Bonanni          BY:   /s/ Malcolm L. Gefter
      --------------------                ---------------------
      FABRIZIO BONANNI                    MALCOLM L. GEFTER
TITLE:SENIOR VICE PRESIDENT               TITLE: CHIEF EXECUTIVE OFFICE AND
      QUALITY & COMPLIANCE                PRESIDENT

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                    EXHIBIT A

VIA FAX AND CERTIFIED MAIL

UCB S.A
Chemin du Foriest
B-1420
Braine-l'Alleud, Belgium

Attn: Alain Scarso, General Manager

Re:   Notice of Assignment

Dear Mr. Scarso:

Reference is made to the Development and Supply Agreement (Abarelix) dated as of
June 21, 2001 by and between UCB S.A. and Amgen Inc. (the "Agreement").
Consistent with recent developments, Amgen and PRAECIS PHARMACEUTICALS
INCORPORATED have agreed to have Amgen assign the Agreement to Praecis in its
entirety. Pursuant to Section 9.3 of the Agreement, this letter will serve to
notify you of the assignment. UCB should direct future notices contemplated in
Section 9.2 of the Agreement to:

         PRAECIS PHARMACEUTICALS INCORPORATED
         830 Winter Street
         Waltham, Massachusetts 02451-1420
         USA

         Attn: Heow Tan
         Vice President, Industrial Operations and Development

Please acknowledge receipt of this notice by signing and returning the enclosed
copy.

Very truly yours,                                Received and acknowledged:

AMGEN INC.                                       UCB S.A.

By: /s/ Fabrizio Bonanni                         By:
    --------------------                             ---------------------------

Title Senior V.P. Quality & Compliance           Title:
      --------------------------------                  ------------------------

Assignment and notice approved by:

PRAECIS PHARMACEUTICALS INCORPORATED

By: /s/ Malcolm Gefter
    ------------------

Title: CEO
       ---------------

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

              CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY
                  WITH THE SECURITIES AND EXCHANGE COMMISSION.
                       ASTERISKS (*) DENOTE SUCH OMISSIONS

                                 AMENDMENT NO. 1

                     TO THE DEVELOPMENT AND SUPPLY AGREEMENT
             SIGNED BETWEEN UCB S.A. AND AMGEN INC. ON 21 JUNE 2000
                         (hereinafter, the "AGREEMENT")

     This Amendment No. 1 to the Agreement (this "Amendment") dated as of March
26, 2002 is entered into by and between UCB S.A. ("UCB") and PRAECIS
PHARMACEUTICALS INCORPORATED ("Praecis").

     WHEREAS, UCB and Amgen Inc. ("Amgen") entered into the Agreement effective
as of June 21, 2000, providing for the development and supply of abarelix API;
and

     WHEREAS, effective as of December 17, 2001, Amgen assigned to Praecis, and
Praecis accepted such assignment and assumed, all of Amgen's rights, interests
and obligations under the Agreement; and

     WHEREAS, UCB and Praecis desire to amend the Agreement to replace certain
Exhibits thereto.

     NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby
agree to amend the Agreement as follows:

1.   AMENDMENT OF EXHIBIT B TO THE AGREEMENT: Exhibit B to the Agreement is
     hereby amended and restated in its entirety and replaced by EXHIBIT B in
     the form attached hereto and incorporated herein by reference.

2.   DELETION OF EXHIBIT E TO THE AGREEMENT: The text of Exhibit E to the
     Agreement is hereby deleted in its entirety and replaced by the following:

     "Intentionally Omitted"

3.   AMENDMENT OF EXHIBIT F TO THE AGREEMENT: Exhibit F to the Agreement is
     hereby amended and restated in its entirety and replaced by EXHIBIT F in
     the form attached hereto and incorporated herein by reference.

4.   DEFINITIONS. Capitalized terms used herein and not otherwise defined shall
     have the meanings ascribed to such terms in the Agreement.

5.   EFFECT OF AMENDMENT. The parties hereto acknowledge that the execution of
     this Amendment in no way serves as an acceptance by UCB of the terms and
     conditions of the Assignment, to the extent such terms and conditions
     relate in any

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

     way to the release of Amgen from its obligations to UCB under the terms of
     the Agreement.

     IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the
date first written above.

PRAECIS PHARMACEUTICALS INCORPORATED       UCB S.A.

By /s/ Kevin F. Mclaughlin                 By /s/ Alain Scarso
   -----------------------                 -------------------
   Name:  Kevin F. McLaughlin              Name:  Alain Scarso
   Title: Senior Vice President and        Title: UCB-Bioproducts, [Illegible]
          Chief Financial Officer

                                           Date:  March 26, 2002
   Date:  March 26, 2002                   Place: Braine-l'Alleud
   Place: Waltham, MA

                                           By /s/ Weiner Deprycher
                                           -----------------------
                                           Name:  Weiner DePrycher
                                           Title: Global Technical [Illegible]

                                           Date:  March 26, 2002
                                           Place: Braine-l'Alleud

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                    EXHIBIT B

                                 QUALITY EXHIBIT

UCB will manufacture abarelix acetate in conformance with all the requirements
of the current Good Manufacturing Practices as described in 21 (CFR), Part 210
and 211, as well as those of other appropriate governing Regulatory Agencies,
and guidance such as ICH Q7a.

1.  ANNUAL PRODUCT REVIEW

    UCB shall conduct an annual review by November 1st of each new-calendar year
    of the commercial services performed by UCB under this Agreement which
    review shall include, but not be limited to, tracking and trending of all
    Batch Records and Manufacturing data. In connection with this annual review,
    UCB shall perform stability testing of at least one Batch per year
    manufactured via each of the syntheses used for commercial production.

2.  AUDITS

    a. ACCESS TO PREMISES. Praecis and its Supplied third Parties may, upon
       prior notice to UCB, have access to and the right to conduct audits of
       those portions of the Facility in which Manufacturing of Product is
       conducted and of applicable UCB procedures during normal hours of
       operation. Routine audits will be conducted annually. "For cause" audits
       will be conducted as needed.

    b. AUDIT FINDINGS. Praecis shall provide UCB with a written report
       summarizing its findings within thirty (30) working days of the
       conclusion of an audit. UCB shall provide Praecis with a written response
       to such report within thirty (30) working days of its receipt thereof.
       Such response shall include a plan for corrective action designed to
       address reasonable concerns and shortcomings documented in the audit
       report.

    c. INSPECTION. In order to ascertain compliance by UCB with the quality
       requirements contained in this Agreement, Praecis and its Supplied Third
       Parties shall have the right, during normal hours of operation and on
       reasonable prior notice to UCB, to inspect and take samples from such
       facilities at which UCB manufactures, tests, sources and/or stores raw
       materials or API. UCB shall use its best efforts to enable Praecis and
       its Affiliates to inspect and sample raw materials used for abarelix and
       coming from the different UCB suppliers. Such inspections and sampling
       shall, to the extent reasonably practicable, be conducted in a manner
       which does not interrupt or impair in any significant manner the
       manufacturing operations of such facilities.

3.  UCB QUALITY ASSURANCE RELEASE PROCEDURES

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

    a. With each completed and released API Batch, UCB shall provide Praecis
       with a batch disposition summary in English language and approved by
       UCB's Quality Compliance (the "Batch Disposition Summary"). ***

    b. The parties will together agree upon the appropriate contents and format
       of the Batch Record Summary, but at a minimum shall include the
       following:

       ***

    c. ***

4.  CHANGE CONTROL

    a. GENERAL. Any changes to be made by UCB which differ from the information
       provided in any Regulatory Agency's filing, as applicable to UCB, shall
       be in compliance with the applicable Regulatory Agency's guidelines,
       including those published by FDA and ICH. Changes to the process,
       equipment, test methods specifications, or other contractual requirements
       must be approved in advance by Praecis prior to implementation.

    b. UCB to provide updated copies of their change control SOP in English
       language to Praecis when effective.

    c. Praecis shall use its best effort to provide response to UCB within15
       business days after receipt of a change request. Changes requiring
       regulatory actions cannot be implemented until such regulatory actions
       are undertaken by Praecis.

5.  DOCUMENTS/STANDARD OPERATING PROCEDURES

       Praecis shall have the right to have access to UCB's SOPs, validation and
       any other documentation relating to Manufacture of API, i.e.,
       deviations/OOS investigations, manufacturing procedures, specifications
       (e.g., purchasing, analytical, raw material, etc), master batch records,
       production recipes, or work orders and any bills of Materials. Upon
       Praecis' request, UCB will provide, at no charge to Praecis, any
       additional processing data as reasonably requested.

6.  RETENTION OF RECORDS

       UCB shall maintain records relating to the API in accordance with cGMP
       (and other regulatory requirements) and shall retain such records for
       not less than ten (10) years after shipment to Praecis of the API to
       which such records related and thereafter such records will be
       transferred to Praecis at Praecis' request. Praecis

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

       shall be entitled to inspect such records at its own expense and at such
       times and intervals as Praecis shall reasonably request upon prior
       written notice to UCB.

7.  REGULATORY INVESTIGATIONS

    a. UCB shall supply Praecis with any manufacturing, testing, or in-process
       control data within forty-eight (48) hours, if requested as the result of
       a regulatory inspection, an annual audit by Praecis, or a potential
       regulatory exposure such as a recall or significant complaint as relates
       to API or Manufacturing services.

    b. UCB is responsible for supporting all Batch Record investigations
       associated with regulatory actions as relates to API or Manufacturing
       services.

    c. UCB shall notify Praecis immediately (but in no event less than twenty
       four (24) hours prior) of any scheduled inspection of the Facility by any
       Regulatory Agency relating to the Manufacture of abarelix. Praecis will
       have the right to be present at all Regulatory Agency inspections of the
       Facility which relate to the Manufacture of abarelix. UCB will disclose
       to Praecis all citations and observations resulting from any Regulatory
       Agency inspection of the Facility as well as responses to the Regulatory
       Agency.

8.  PRODUCT ACCEPTANCE OR REJECTION PROCEDURES

    a. All API batches must have UCB's Quality Compliance release and Praecis'
       Quality Assurance written disposition prior to shipment by UCB. ***

    b. RECORDS ACCOMPANYING SHIPMENT. All shipments of API by UCB shall include
       UCB Quality Compliance written approval of such Batch and MSDS, i.e.,
       UCB's certificate of analysis that such API meets the specifications,
       certificate of conformance, and raw material source statement.

    c. REJECTION. Praecis, at its sole discretion, may perform testing of the
       API for compliance with the Specifications. Praecis may reject any Batch
       of API failing to meet any of the Specifications by giving written notice
       of rejection to UCB within ninety (90) days, following receipt by Praecis
       of UCB Quality Compliance written approval of such Batch and the
       applicable Batch Disposition Summary. Any claim by Praecis submitted to
       UCB pursuant to this Section 8 shall be accompanied by a report of
       analysis (including a product sample from the Batch analyzed). Praecis'
       failure to reject API in the manner set forth herein shall constitute
       acceptance thereof except to the extent that any defect in the Batch,
       which defect substantially impairs the value of the Batch to Praecis and
       which would have otherwise permitted Praecis to reject such Batch
       pursuant to this Section, was not discovered by Praecis after exercising
       due diligence and using customary testing procedures accepted in the
       industry and provided that Praecis notifies UCB of any such defect within
       a reasonable time after Praecis discovers or should have discovered the
       defect and before any substantial change in the condition of the Batch
       which is not caused by such defect.

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

9.  PRODUCT COMPLAINTS

       Praecis will promptly notify UCB of any Product complaints received by
       Praecis which may be related to the API manufactured by UCB. Praecis will
       provide details of the complaint along with the notification. Within
       thirty (30) calendar days of UCB's receipt of such notification, UCB
       shall provide Praecis with a report reconciling the reported complaint to
       UCB's operating procedures.

10. SUBCONTRACTORS

       UCB shall consult with Praecis prior to use of subcontractors in support
       of this project. Praecis will evaluate and submit approval within a
       reasonable time.

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                    EXHIBIT E

                             "Intentionally Omitted"

<Page>

                                                             FOIA CONFIDENTIAL
                                                          TREATMENT REQUESTED***

                                    EXHIBIT F

                       PRAECIS AUTHORIZED REPRESENTATIVES
<Table>
<S>                            <C>
Gary Musso                     Technical
Heow Tan                       Secondary Technical
Mary Ellen Streeton            Quality Assurance
Jim Majewski                   Secondary Quality Assurance
JD Bernardy                    Regulatory Affairs
Kevin McLaughlin               Corporate
</Table>

                         UCB AUTHORIZED REPRESENTATIVES
<Table>
<S>                            <C>
Laurent Schinckus              Contract Manufacturing
Pascal Brouyere                Technical
Nathalie Dubois                Quality Assurance
Nathalie Dubois                Regulatory Affairs
Alain Scarso                   Corporate
Vincent Bille                  Secondary Corporate
</Table><Page>

                                                                        EX 10.17

                     FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

EFFECTIVE DATE: AS OF JANUARY 1, 2001

WOOLEY:         {NAME}

COMPANY:        SCHLOTZSKY'S, INC., a Texas corporation
                203 Colorado Street
                Austin, Texas  78701

AGREEMENT:      Amended and Restated Employment Agreement, effective as of
                January 1, 2001, by and between WOOLEY and COMPANY.

WHEREAS, the Parties listed above entered into the AGREEMENT described above;
and

WHEREAS, WOOLEY and COMPANY have determined that it is in their mutual best
interest to modify the terms of the AGREEMENT; and

WHEREAS, this amendment has been approved by an action of the Compensation
Committee of the Board of Directors of the COMPANY dated December 28, 2001;

NOW, THEREFORE, for the mutual obligations contained herein and other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Parties agree as follows:

1. EFFECT OF AMENDMENT. The AGREEMENT is hereby supplemented and modified by the
provisions of this First Amendment to Employment Agreement ("AMENDMENT").
Wherever there is any conflict between the provisions of the AGREEMENT and the
provisions of this AMENDMENT, the provisions of this AMENDMENT are paramount and
shall control, and the AGREEMENT shall be construed accordingly. Any terms that
are defined in the AGREEMENT shall have the same meanings in this AMENDMENT. Any
provision in the AGREEMENT not expressly changed by or inconsistent with the
provisions of this AMENDMENT shall remain the same.

2. AMENDMENT OF ADVANCE. The AGREEMENT is hereby amended to restate Section 5 as
follows:

     5. ADVANCE. On or before January 31, 2001, the Company shall pay Wooley a
     cash advance against Wooley's future bonuses earned in the amount of
     ${Amount of Advance}. The advance shall be recovered by applying the
     following amounts until the full amount is recovered: ${One-Third of
     Advance} of the 2002 bonus, ${One-Third of Advance} of the 2003 bonus, and
     ${One-Third of Advance} of the 2004 bonus. If all or any portion of the
     advance remains after application of the 2004 bonus, such remainder shall
     be deemed fully earned by Wooley and not to be recovered by the Company.

3. AMENDMENT REGARDING STOCK OPTIONS. The AGREEMENT is hereby amended to restate
Section 6 as follows:

     6. [This Section is intentionally omitted in its entirety.]

<Page>

IN WITNESS WHEREOF, the parties hereto have executed this original of this
AMENDMENT to be effective on the EFFECTIVE DATE.

COMPANY:
SCHLOTZSKY'S, INC.,
a Texas corporation

By:
        --------------------------------------
        Richard H. Valade
Title:  Executive Vice President & Treasurer
        Chief Financial Officer

WOOLEY:

----------------------------------------------
        {Name}

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]